Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Mirtax is a generic mirtazapine widely used since 2003. We conducted an open-label, uncontrolled 6-week study to evaluate the efficacy and safety of Mirtax for major depressive disorder (MDD). Methods: Ninety three MDD patients with the diagnosis of MDD and 17-item Hamilton Depression Rating Scale (HDRS) score ≥14 were recruited. The HDRS, Montgomery-Åsberg Depression Rating Scale (MADRS), and the Clinical Global Impressions-Severity Scale (CGI-S) were administered at baseline, 1, 2, 4 and 6 weeks. Response (≥50% decrease in the HDRS or MADRS score), remission (absolute HDRS score ≤7 or MADRS score ≤10) and CGI-I score ≤2 were also calculated. Adverse event (AE) frequency and severity, weight, blood pressure, and pulse rate were checked to assess safety. Results: The starting dosage was 11.5±6.4 mg/day, and the maintenance dosage was 23.1±9.4 mg/day. During 6 weeks, HDRS, MADRS and CGI-S scores decreased from 25.1±5.6 to 11.9±8.6 (mean change –13.1±8.3, p＜0.001), from 30.2±6.3 to 13.73±10.40 (mean change –16.5±9.8, p＜0.001), and from 5.0±0.8 to 2.5±1.3 (mean change –2.5±1.3, p＜0.001), respectively. The percentages of responders, remitters by HDRS and patients with a CGI-I score ≤2 were 64.6%, 35.4% and 52.7%, respectively. Significant decreases in HDRS, MADRS and CGI-S scores were confirmed at week 1. The total rate of AEs was 32.3%; the most frequently reported AEs were sedation (4.3%) and constipation (4.3%). Weight was increased from 58.8±10.6 to 60.3±9.3 kg (mean change 0.7±1.7 kg, p=0.004). Conclusion: This study, as the first clinical trial of generic mirtazapine, demonstrated the efficacy and tolerability of Mirtax for MDD using a single treatment design.
Abstract
Objective: Mirtax is a generic mirtazapine widely used since 2003. We conducted an open-label, uncontrolled 6-week study to evaluate the efficacy and safety of Mirtax for major depressive disorder (MDD). Methods: Ninety three MDD patients with the diagnosis of MDD and 17-item Hamilton Depression Rating Scale (HDRS) score ≥14 were recruited. The HDRS, Montgomery-Åsberg Depression Rating Scale (MADRS), and the Clinical Global Impressions-Severity Scale (CGI-S) were administered at baseline, 1, 2, 4 and 6 weeks. Response (≥50% decrease in the HDRS or MADRS score), remission (absolute HDRS score ≤7 or MADRS score ≤10) and CGI-I score ≤2 were also calculated. Adverse event (AE) frequency and severity, weight, blood pressure, and pulse rate were checked to assess safety. Results: The starting dosage was 11.5±6.4 mg/day, and the maintenance dosage was 23.1±9.4 mg/day. During 6 weeks, HDRS, MADRS and CGI-S scores decreased from 25.1±5.6 to 11.9±8.6 (mean change –13.1±8.3, p＜0.001), from 30.2±6.3 to 13.73±10.40 (mean change –16.5±9.8, p＜0.001), and from 5.0±0.8 to 2.5±1.3 (mean change –2.5±1.3, p＜0.001), respectively. The percentages of responders, remitters by HDRS and patients with a CGI-I score ≤2 were 64.6%, 35.4% and 52.7%, respectively. Significant decreases in HDRS, MADRS and CGI-S scores were confirmed at week 1. The total rate of AEs was 32.3%; the most frequently reported AEs were sedation (4.3%) and constipation (4.3%). Weight was increased from 58.8±10.6 to 60.3±9.3 kg (mean change 0.7±1.7 kg, p=0.004). Conclusion: This study, as the first clinical trial of generic mirtazapine, demonstrated the efficacy and tolerability of Mirtax for MDD using a single treatment design.
참고문헌 (25)
- Kessler RC., "The global burden of mental disorders : an update from the WHO World Mental Health(WMH)surveys", Epidemiol Psichiatr Soc, 18, pp.23~33 (2009)
- Szegedi A., "Mirtazapine : a review of its clinical efficacy and tolerability", Expert Opin Pharmacother, 6, pp.631~641 (2005)
- Thompson C., "Mirtazapine versus selective serotonin reuptake inhibitors", J Clin Psychiatry, 60(Suppl 17), pp.18~22 (1999)
- Benkert O., "Mirtazapine orally disintegrating tablets versus venlafaxine extended release : a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder", J Clin Psychopharmacol, 26, pp.75~78 (2006)
- Benjamin S., "Review of the use of mirtazapine in the treatment of depression", Expert Opin Pharmacother, 12, pp.1623~1632 (2011)
- Borgheini G., "The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs", Clin Ther, 25, pp.1578~1592 (2003)
- Margolese HC., "Loss of response after switching from brand name to generic formulations : three cases and a discussion of key clinical considerations when switching", Int Clin Psychopharmacol, 25, pp.180~182 (2010)
- Pae CU., "Paroxetine mesylate : comparable to paroxetine hydrochloride?", Expert Opin Pharmacother, 11, pp.185~193 (2010)
- Williams JB., "A structured interview guide for the Hamilton Depression Rating Scale", Arch Gen Psychiatry, 45, pp.742~747 (1988)
- Williams JB., "Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale(SIGMA)", Br J Psychiatry, 192, pp.52~58 (2008)
- Busner J., "The clinical global impressions scale : applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
- Frank E., "Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence", Arch Gen Psychiatry, 48, pp.851~855 (1991)
- Wheatley DP., "Mirtazapine : efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group", J Clin Psychiatry, 59, pp.306~312 (1998)
- Benkert O., "Mirtazapine compared with paroxetine in major depression", J Clin Psychiatry, 61, pp.656~663 (2000)
- Hong CJ., "A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients", J Clin Psychiatry, 64, pp.921~926 (2003)
- Papakostas GI., "A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder", J Psychopharmacol, 22, pp.843~848 (2008)
- Thase ME., "Remission with mirtazapine and selective serotonin reuptake inhibitors : a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression", Int Clin Psychopharmacol, 25, pp.189~198 (2010)
- Watanabe N., "Mirtazapine versus other antidepressive agents for depression", Cochrane Database Syst Rev, (12), pp.CD006528~ (2011)
- Quitkin FM., "Does mirtazapine have a more rapid onset than SSRIs?", J Clin Psychiatry, 62, pp.358~361 (2001)
- Leinonen E., "Efficacy and tolerability of mirtazapine versus citalopram : a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group", Int Clin Psychopharmacol, 14, pp.329~337 (1999)
- Claghorn JL., "A double-blind placebo-controlled study of Org 3770 in depressed outpatients", J Affect Disord, 34, pp.165~171 (1995)
- Vartiainen H., "Double-blind study of mirtazapine and placebo in hospitalized patients with major depression", Eur Neuropsychopharmacol, 4, pp.145~150 (1994)
- Dewan MJ., "Evaluating the tolerability of the newer antidepressants", J Nerv Ment Dis, 187, pp.96~101 (1999)
- Kasper S., "A risk-benefit assessment of mirtazapine in the treatment of depression", Drug Saf, 17, pp.251~264 (1997)
- Iwamoto K., "Effects of low-dose mirtazapine on driving performance in healthy volunteers", Hum Psychopharmacol, 28, pp.523~528 (2013)